Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

PanOptica completes $30 million Series A financing

PanOptica, Inc., a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies, today announced that it has raised $30 million in a Series A financing. This round was led by SV Life Sciences and Third Rock Ventures.

4 Jan 2011

Lyophilized amniotic membrane in strabismus surgery can cause severe fibrosis

Postoperative adhesions are a major complication in strabismus surgery. Amniotic membrane has been used in the hopes of preventing these adhesions by forming a biological barrier during healing. In an article in the December 2010 issue of the Journal of AAPOS, a team of researchers from Cairo University have discovered that the new approach may also have the opposite effect.

4 Jan 2011

Los Angeles Magazine declares LA BioMed physicians as 2011 Southern California Super Doctors

A select 40 physician-researchers at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center were named 2011 Southern California Super Doctors in the January issue of Los Angeles Magazine.

4 Jan 2011

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to treat Dry Age-Related Macular Degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

3 Jan 2011

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Inspire Pharmaceuticals, Inc. announced today the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis.

3 Jan 2011

NEI awards Case Western Reserve $10M for study of retinal diseases

The Departments of Pharmacology and Ophthalmology and Visual Sciences at Case Western Reserve University School of Medicine have been awarded a $10.1 million grant from the National Eye Institute (NEI) to research and develop new treatments for diseases of the retina, a leading cause of blindness.

29 Dec 2010

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.

23 Dec 2010

NextGen Healthcare announces partnership with Wills Eye for meaningful use

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Wills Eye Health System to deploy NextGen® Ambulatory EHR and NextGen® Practice Management.

16 Dec 2010

Vision community, FDA discuss use of PROs to improve labeling of ophthalmic treatments, products

The vision community is discussing with the Food and Drug Administration how vision-related patient-reported outcomes might be used in improving the labeling of ophthalmic treatments and products. The group — composed of researchers, clinicians, policymakers and representatives from industry and vision associations — attended a one-day symposium sponsored by the National Institutes of Health's National Eye Institute and the FDA on October 13, 2009.

8 Dec 2010

Closer to restoring vision loss due to optic nerve damage

Damage to the optic nerve, connecting the eye with the brain, is a major cause of blindness. The most common culprit is glaucoma, estimated to affect more than 4 million Americans. There is currently no way to restore the lost vision, because the optic nerve, like other nerves in the mature central nervous system (CNS), cannot regenerate. Now, scientists at Children's Hospital Boston report achieving the greatest regeneration to date in the mammalian optic nerve.

4 Dec 2010

ACT files IND application to initiate Phase I/II study for Dry AMD

Advanced Cell Technology, Inc. announced today that it has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration (Dry AMD).

30 Nov 2010

Total Immersion adds Vantage Surgical Systems to North American AR Partner network

Total Immersion, the global leader in augmented reality (AR), today announced the addition of Vantage Surgical Systems as a Certified D'Fusion Value Added Reseller to its North American Partner network, the world's largest network dedicated to AR.

30 Nov 2010

HOYA Vision Care discusses technological developments and future of progressive lenses at Global PAL Summit

From 27 September until 1 October HOYA Vision Care invited a selection of its best lens experts and VIP customers from all over the world to join its Global PAL Summit in La Toja, Spain. Goal was to discuss in depth new technological developments and share vision and plans on the future generation progressive lenses.

24 Nov 2010

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

OptiMedica's Catalys Precision Laser System improves precision in cataract surgery

Global ophthalmic device company OptiMedica Corp. has announced that results from a clinical study of its Catalys Precision Laser System were published in the peer-reviewed journal Science Translational Medicine.

18 Nov 2010

Krieger Eye Institute at Sinai Hospital opens new center for treatment of retinal diseases

The Krieger Eye Institute at Sinai Hospital opened a new center for the treatment of retinal diseases in November. The retina is the layer of tissue at the back of the eye that converts images to electrical impulses. These electrical signals are then perceived by the brain as sight.

18 Nov 2010

Popular Science names VisionCare's Implantable Miniature Telescope for AMD 'Best of What's New' 2010

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices, today announced the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), designed to improve vision in patients with end-stage age-related macular degeneration (AMD) is named "Best of What's New" 2010 by Popular Science magazine.

17 Nov 2010

Study reveals true effects of malaria on African generations

Almost a third of cerebral malaria survivors developed epilepsy or other behavioral disorders in the most comprehensive study to date of the disease in African children, solidifying the link between malaria and neuropsychiatric disorders that affect hundreds of thousands of children.

17 Nov 2010

Tobii launches TX300 Eye Tracker for linguistics and behavioral research

Tobii Technology, the global market leader in eye tracking, announced today its new Tobii TX300™ Eye Tracker. The TX300 is the first higher-frequency eye-tracking hardware that allows research subjects the freedom of head movement, which helps scientists create more realistic testing environments for detailed and efficient research of natural behavior and higher definition samplings at 300 hertz.

11 Nov 2010

Ophthalmology News and Research

Further Reading

PanOptica completes $30 million Series A financing

Lyophilized amniotic membrane in strabismus surgery can cause severe fibrosis

Los Angeles Magazine declares LA BioMed physicians as 2011 Southern California Super Doctors

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

NEI awards Case Western Reserve $10M for study of retinal diseases

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

NextGen Healthcare announces partnership with Wills Eye for meaningful use

Vision community, FDA discuss use of PROs to improve labeling of ophthalmic treatments, products

Closer to restoring vision loss due to optic nerve damage

ACT files IND application to initiate Phase I/II study for Dry AMD

Total Immersion adds Vantage Surgical Systems to North American AR Partner network

HOYA Vision Care discusses technological developments and future of progressive lenses at Global PAL Summit

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

OptiMedica's Catalys Precision Laser System improves precision in cataract surgery

Krieger Eye Institute at Sinai Hospital opens new center for treatment of retinal diseases

Popular Science names VisionCare's Implantable Miniature Telescope for AMD 'Best of What's New' 2010

Study reveals true effects of malaria on African generations

Tobii launches TX300 Eye Tracker for linguistics and behavioral research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News